Observational studyAnnals of hematology2020

Real-world effectiveness and safety of ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma.

Evangelos Terpos et al.PubMed ↗Publisher ↗

No numbers read from the abstract.